newsfilter
← Latest News
GlobeNewswire·

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support